Teijin Ltd (3401.T)
2,010JPY
19 Oct 2018
¥-20 (-0.99%)
¥2,030
¥2,010
¥2,013
¥1,992
1,210,600
1,076,550
¥2,603
¥1,954
Latest Key Developments (Source: Significant Developments)
Teijin lowers conversion price for 2018 due and 2021 due euro-yen denominated convertible bonds
May 9(Reuters) - Teijin Ltd <3401.T>:Says it lowers the conversion price for 2018 due euro-yen denominated convertible bonds to 1,998.6 yen per share, from 2,026.0 yen per share.Says it lowers the conversion price for 2021 due euro-yen denominated convertible bonds to 1,964.7 yen per share, from 1,991.7 yen per share.Effective April 1. Full Article
Infocom to acquire 9.8 pct stake in Papyless
March 28 (Reuters) - Infocom Corp <4348.T>:Says it will acquire 9.8 percent stake (969,500 shares) in Papyless Co Ltd <<<3641.T>>> on March 29 . Full Article
Teijin to merge with fiber unit
Nov 30(Reuters) - Teijin Ltd <3401.T>:Says it will merge with a Tokyo-based fiber consolidated subsidiary.Merger effective April 1, 2018.Says the subsidiary will be dissolved after the merger . Full Article
R&I affirms Teijin's rating at "A-" and says stable outlook -R&I
Nov 16 (Reuters) - Teijin Ltd <3401.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A-" -R&I.Says rating outlook stable -R&I. Full Article
Teijin lowers conversion price for 2018 due euro-yen denominated convertible bonds and 2021 due euro-yen denominated convertible bonds
Nov 2 (Reuters) - Teijin Ltd <3401.T>:Says it lowered the conversion price for 2018 due euro-yen denominated convertible bonds to 2,026 yen per share, from 2,035.7 yen per share, after Oct. 1 .Says it lowered the conversion price for 2021 due euro-yen denominated convertible bonds to 1,991.7 yen per share, from 2,001.3 yen per share, after Oct. 1 . Full Article
Merz, Teijin announce partnership to bring Xeomin to Japan
Oct 12 (Reuters) - Teijin Ltd <3401.T>::Merz and Teijin announce partnership to bring Xeomin (Incobotulinumtoxina) to Japan.Entered into strategic license and co-development agreement with merz for commercialization of xeomin (incobotulinumtoxina) for Japan.Merz sponsors 2 clinical trials in Japan covering spasticity of upper, lower limbs; upper limb trial completion seen in 2018.Under terms of agreement, Merz will receive an upfront payment in addition to milestones and royalties. Full Article
Teijin says co-sale of equity interests in film business joint ventures
Oct 11 (Reuters) - Teijin Ltd <3401.T>:* Says it will jointly sell all of the. Full Article
Teijin to transfer rights and obligations to unit TEIJIN FRONTIER
July 31(Reuters) - Teijin Ltd <3401.T>:Says it will transfer rights and obligations, including inventories, investment securities and capital invested into group company, to wholly owned unit TEIJIN FRONTIER CO., LTD..Effective Oct. 1. Full Article
JCR Pharmaceuticals to develop allogeneic regenerative medical product using DPCs with Teijin
July 18(Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it entered into co-development and license agreement with Teijin Ltd <<<3401.T>>>, regarding JTR-161, an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction (stroke) for Japan, on July 18. Full Article
Radius Health announces license and development agreement for Abaloparatide-Sc with Teijin Limited in Japan
July 13 (Reuters) - Radius Health Inc
Earnings vs. 
Estimates